Spirodiketopiperazine-based CCR5 antagonist: Discovery of an antiretroviral drug candidate

被引：9

作者：

Nishizawa, Rena ^{[1
]}

Nishiyama, Toshihiko ^{[1
]}

Hisaichi, Katsuya ^{[1
]}

Minamoto, Chiaki ^{[1
]}

Matsunaga, Naoki ^{[1
]}

Takaoka, Yoshikazu ^{[1
]}

Nakai, Hisao ^{[1
]}

Jenkinson, Stephen ^{[3
]}

Kazmierski, Wieslaw M. ^{[3
]}

Tada, Hideaki ^{[2
]}

Sagawa, Kenji ^{[2
]}

Shibayama, Shiro ^{[2
]}

Fukushima, Daikichi ^{[2
]}

Maeda, Kenji ^{[4
,5
]}

Mitsuya, Hiroaki ^{[4
,5
]}

机构：

[1] Ono Pharmaceut Co Ltd, Med Chem Res Lab, Osaka 6188585, Japan

[2] Ono Pharmaceut Co Ltd, Exploratory Res Lab, Ibaraki 300424, Japan

[3] GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC 27709 USA

[4] Kumamoto Univ, Sch Med, Dept Internal Med 2, Kumamoto 8600811, Japan

[5] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 04期

关键词：

CCR5; Chemokine; Anti-HIV; CHEMOKINE RECEPTOR; HIV-1; INFECTION; VIRAL ENTRY; CORECEPTOR; COFACTOR; POTENT;

D O I：

10.1016/j.bmcl.2010.12.109

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Following the discovery that hydroxylated derivative 3 (Fig. 1) was one of the oxidative metabolites of the original lead 1, it was found that hydroxylated compound 4 possesses higher in vitro anti-HIV potency than the corresponding non-hydroxylated compound 2. Structural hybridation of 4 with the orally available analog 5 resulted in another orally-available spirodiketopiperazine CCR5 antagonist 6a that possesses more favorable pharmaceutical profile for use as a drug candidate. (c) 2010 Elsevier Ltd. All rights reserved.

引用

页码：1141 / 1145

页数：5

共 50 条

[1] Discovery of orally available spirodiketopiperazine-based CCR5 antagonists
Nishizawa, Rena
Nishiyama, Toshihiko
Hisaichi, Katsuya
Hirai, Keisuke
Habashita, Hiromu
Takaoka, Yoshikazu
Tada, Hideaki
Sagawa, Kenji
Shibayama, Shiro
Maeda, Kenji
Mitsuya, Hiroaki
Nakai, Hisao
Fukushima, Daikichi
Toda, Masaaki
BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (14) : 5208 - 5223
[2] Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles
Nishizawa, Rena
Nishiyama, Toshihiko
Hisaichi, Katsuya
Hirai, Keisuke
Habashita, Hiromu
Takaoka, Yoshikazu
Tada, Hideaki
Sagawa, Kenji
Shibayama, Shiro
Maeda, Kenji
Mitsuya, Hiroaki
Nakai, Hisao
Fukushima, Daikichi
Toda, Masaaki
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (02) : 763 - 766
[3] Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite
Nishizawa, Rena
Nishiyama, Toshihiko
Hisaichi, Katsuya
Matsunaga, Naoki
Minamoto, Chiaki
Habashitaa, Hiromu
Takaoka, Yoshikazu
Toda, Masaaki
Shibayama, Shiro
Tada, Hideaki
Sagawa, Kenji
Fukushima, Daikichi
Maeda, Kenji
Mitsuya, Hiroaki
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (03) : 727 - 731
[4] Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-Chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro
Maeda, K
Nakata, H
Koh, Y
Miyakawa, T
Ogata, H
Takaoka, Y
Shibayama, S
Sagawa, K
Fukushima, D
Moravek, J
Koyanagi, Y
Mitsuya, H
JOURNAL OF VIROLOGY, 2004, 78 (16) : 8654 - 8662
[5] Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc
Price, David A.
Armour, Duncan
de Groot, Marcel
Leishman, Derek
Napier, Carolyn
Perros, Manos
Stammen, Blanda L.
Wood, Anthony
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (17) : 4633 - 4637
[6] Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist
Pasternak, Alexander
Goble, Stephen D.
Struthers, Mary
Vicario, Pasquale P.
Ayala, Julia M.
Di Salvo, Jerry
Kilburn, Ruth
Wisniewski, Thomas
DeMartino, Julie A.
Mills, Sander G.
Yang, Lihu
ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (01): : 14 - 18
[7] Maraviroc: a new CCR5 antagonist
Sayana, Shilpa
Khanlou, Homayoon
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (01) : 9 - 19
[8] Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
Liu, Yanqing
Zhou, Enkun
Yu, Kunqian
Zhu, Jin
Zhang, Yu
Xie, Xin
Li, Jian
Jiang, Hualiang
MOLECULES, 2008, 13 (10) : 2426 - 2441
[9] Overcoming hERG affinity in the discovery of maraviroc; A CCR5 antagonist for the treatment of HIV
Price, David A.
Armour, Duncan
de Groot, Marcel
Leishman, Derek
Napier, Carolyn
Perros, Manos
Stammen, Blanda L.
Wood, Anthony
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (13) : 1140 - 1151
[10] BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate
Cherney, Robert J.
Anjanappa, Prakash
Selvakumar, Kumaravel
Batt, Douglas G.
Brown, Gregory D.
Rose, Anne, V
Vuppugalla, Ragini
Chen, Jing
Pang, Jian
Xu, Songmei
Yarde, Melissa
Tebben, Andrew J.
Paidi, Venkatram Reddy
Cvijic, Mary Ellen
Mathur, Arvind
Barrish, Joel C.
Mandlekar, Sandhya
Zhao, Qihong
Carter, Percy H.
ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (11): : 1753 - 1758

← 1 2 3 4 5 →